TOKYO, May 14 (Pulse News Wire) – Renascience Inc. (4889.T) reported interim results from its semi-final clinical trial in the XPRIZE Healthspan competition.
The trial involved 20 patients aged 50 to 75 with stable chronic conditions such as hypertension, diabetes, and kidney disease. After four months of treatment with RS7, patients showed significant biological age reduction averaging 2-3 years based on epigenetic markers. Additionally, improvements were observed in immune function, muscle regeneration, cognitive abilities, and antioxidant levels. Safety data indicated mild liver dysfunction in one patient but no severe adverse events.
The study also revealed reductions in senescence-related microRNAs and proteins associated with inflammation and metabolic disorders. Further analysis of hematopoietic stem cells suggested enhanced regenerative capacity. Renascience plans to submit final trial proposals to the XPRIZE Healthspan evaluation committee by mid-April 2026. If selected as finalists, the team will conduct international multicenter trials involving up to 150 elderly subjects across multiple countries.
🟢 Confidence: High AI-translated content.